| 3.6 -0.09 (-2.44%) | 02-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.69  |
1-year : | 5.06 |
| Resists | First : | 4.01 |
Second : | 4.34 |
| Pivot price | 3.69 |
|||
| Supports | First : | 3.5 | Second : | 2.91 |
| MAs | MA(5) : | 3.64  |
MA(20) : | 3.74 |
| MA(100) : | 4.05 |
MA(250) : | 4.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.6 |
D(3) : | 23.6 |
| RSI | RSI(14): 41.7 | |||
| 52-week | High : | 6.75 | Low : | 3.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLGN ] has closed above bottom band by 21.2%. Bollinger Bands are 56.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.71 - 3.72 | 3.72 - 3.73 |
| Low: | 3.56 - 3.58 | 3.58 - 3.59 |
| Close: | 3.57 - 3.6 | 3.6 - 3.62 |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Fri, 14 Feb 2025
D. Boral Capital Reaffirms “Buy” Rating for CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
Wed, 12 Feb 2025
CollPlant Biotechnologies Provides a Corporate Update - Quantisnow
Wed, 12 Feb 2025
Major Patent Win: CollPlant's Revolutionary Dermal Filler Technology Secures Protection Until 2039 - StockTitan
Mon, 20 Jan 2025
Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Pathfinder Cell Therapy (OTCMKTS:PFND) - Defense World
Wed, 27 Nov 2024
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - PR Newswire
Tue, 12 Nov 2024
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 7.65e+006 (%) |
| Held by Institutions | 10.1 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.727e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -113 % |
| Return on Assets (ttm) | 550 % |
| Return on Equity (ttm) | -38.3 % |
| Qtrly Rev. Growth | 650000 % |
| Gross Profit (p.s.) | -143.97 |
| Sales Per Share | -112.15 |
| EBITDA (p.s.) | -2.34921e+006 |
| Qtrly Earnings Growth | -1.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 1.53 |
| Dividend | 0 |
| Forward Dividend | 13910 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|